Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)

Summary

To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.

Timeline

Start

2014-08

Primary completion

2018-03

Completion

2018-03

Drugs

Indications